Summary
For Year 2026-27, Concord Drugs reports the following shareholding: Total Promoters at 54.39%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 45.61%. This breakdown provides a quick snapshot of ownership distribution for Concord Drugs in 2026-27.
Concord Drugs FAQs
As of 04-2026, the promoter shareholding in Concord Drugs stands at 54.39% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Concord Drugs is 0% and 0% respectively.
The retail shareholding of the Concord Drugs is 45.61%.
Changes in shareholding patterns of Concord Drugs can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Concord Drugs are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
